Source:http://linkedlifedata.com/resource/pubmed/id/19711347
Switch to
| Predicate | Object |
|---|---|
| rdf:type | |
| lifeskim:mentions | |
| pubmed:issue |
6
|
| pubmed:dateCreated |
2010-1-25
|
| pubmed:abstractText |
The present study investigated the preventive effects of etodolac, a selective cyclo-oxygenase (COX)-2 inhibitor, on metachronous cancer development after endoscopic resection of early gastric cancer. Among 267 early gastric cancer patients who underwent endoscopic resection, 47 patients with extensive metaplastic gastritis were selected based on endoscopic findings and our previously described criteria of serum pepsinogen (PG) test-positive and Helicobacter pylori antibody-negative conditions. Nonrandomized etodolac treatment (300 mg/day) was administered to 26 patients (Group A), while the remaining 21 patients were untreated (Group B). No significant differences in age, sex distribution, lifestyle factors or extent of metaplastic gastritis at baseline were identified between groups. Patients were followed for metachronous cancer development with endoscopy every 6-12 months for up to 5 years. Mean (standard deviation) follow-up period was 4.2 (0.9) years. In Group B, 5 cancers developed (incidence rate = 6,266/100,000 person-years), significantly more than the 1 cancer in Group A (incidence rate = 898/100,000 person-years; p < 0.05). Long-term etodolac treatment did not influence the extent of metaplastic gastritis as revealed by endoscopic findings or by serum PG levels, but effectively reduced metachronous cancer development in patients with extensive metaplastic gastritis. These results strongly suggest that chemoprevention of cancer in the metaplastic stomach is possible by controlling COX-2 expression.
|
| pubmed:language |
eng
|
| pubmed:journal | |
| pubmed:citationSubset |
IM
|
| pubmed:chemical | |
| pubmed:status |
MEDLINE
|
| pubmed:month |
Mar
|
| pubmed:issn |
1097-0215
|
| pubmed:author |
pubmed-author:DeguchiHisanobuH,
pubmed-author:EnomotoShotaroS,
pubmed-author:FujishiroMitsuhiroM,
pubmed-author:HillToddT,
pubmed-author:IchinoseMasaoM,
pubmed-author:IguchiMikitakaM,
pubmed-author:InadaKenichiK,
pubmed-author:MaekitaTakaoT,
pubmed-author:MukoubayashiChizuC,
pubmed-author:NakamuraYasushiY,
pubmed-author:OkaMasashiM,
pubmed-author:TakeshitaTatsuyaT,
pubmed-author:TamaiHideyukiH,
pubmed-author:TsukamotoTetsuyaT,
pubmed-author:UedaKazukiK,
pubmed-author:UtsunomiyaHirotoshiH,
pubmed-author:YanaokaKimihikoK,
pubmed-author:YoshimuraNorikoN
|
| pubmed:issnType |
Electronic
|
| pubmed:day |
15
|
| pubmed:volume |
126
|
| pubmed:owner |
NLM
|
| pubmed:authorsComplete |
Y
|
| pubmed:pagination |
1467-73
|
| pubmed:dateRevised |
2010-11-18
|
| pubmed:meshHeading |
pubmed-meshheading:19711347-Aged,
pubmed-meshheading:19711347-Cyclooxygenase 2 Inhibitors,
pubmed-meshheading:19711347-Etodolac,
pubmed-meshheading:19711347-Female,
pubmed-meshheading:19711347-Follow-Up Studies,
pubmed-meshheading:19711347-Gastritis,
pubmed-meshheading:19711347-Helicobacter pylori,
pubmed-meshheading:19711347-Humans,
pubmed-meshheading:19711347-Kaplan-Meier Estimate,
pubmed-meshheading:19711347-Male,
pubmed-meshheading:19711347-Middle Aged,
pubmed-meshheading:19711347-Precancerous Conditions,
pubmed-meshheading:19711347-Stomach,
pubmed-meshheading:19711347-Stomach Neoplasms,
pubmed-meshheading:19711347-Treatment Outcome
|
| pubmed:year |
2010
|
| pubmed:articleTitle |
Preventive effects of etodolac, a selective cyclooxygenase-2 inhibitor, on cancer development in extensive metaplastic gastritis, a Helicobacter pylori-negative precancerous lesion.
|
| pubmed:affiliation |
Department of Gastroenterology, School of Medicine, Wakayama Medical University, Wakayama City, Wakayama 641-0012, Japan.
|
| pubmed:publicationType |
Journal Article,
Clinical Trial,
Research Support, Non-U.S. Gov't
|